Pulmonary fibrosis is a condition in which the tissue deep inside your lungs becomes scarred and stiff, making it progressively harder to breathe. The scarring thickens the walls between the air sacs where oxygen enters your bloodstream, so less oxygen reaches your body with each breath. It’s a chronic, progressive disease, and in its most common form, idiopathic pulmonary fibrosis (IPF), median survival is 3 to 5 years after diagnosis.
What Happens Inside the Lungs
Healthy lungs are soft and elastic. When you inhale, tiny air sacs called alveoli expand and pass oxygen through their thin walls into your blood. In pulmonary fibrosis, something triggers damage to the cells lining those air sacs. The damaged tissue releases chemical signals, most importantly a growth factor called TGF-β1, that activate nearby repair cells called fibroblasts.
Normally, fibroblasts help heal wounds and then quiet down. In pulmonary fibrosis, they shift into an overactive state, transforming into cells called myofibroblasts that produce enormous amounts of collagen and other structural proteins. This excess material builds up in the lung tissue, forming stiff, fibrous scar tissue that replaces the soft, flexible walls of the air sacs. Over time, patches of scarring spread and merge, and the lungs lose their ability to expand fully or transfer oxygen efficiently.
Known Causes and Risk Factors
Pulmonary fibrosis can develop from a range of identifiable triggers. Inhaling harmful particles over months or years is one of the most established causes. Silica dust, commonly encountered in mining, sandblasting, and construction, provokes a chain reaction of inflammation and scarring. Studies show that 16% to 20% of silica-exposed workers who developed lung disease had scarring patterns consistent with pulmonary fibrosis on imaging. Asbestos exposure, particularly in metalworking and construction industries, carries a similar risk. Other occupational and environmental exposures include coal dust, grain dust, and bird droppings.
Autoimmune conditions like rheumatoid arthritis, lupus, and scleroderma can cause lung scarring as part of their broader pattern of tissue inflammation. Certain medications, including some chemotherapy drugs and heart rhythm medications, can also trigger it. Radiation therapy to the chest is another recognized cause.
In many cases, though, no cause is ever identified. This is called idiopathic pulmonary fibrosis, and it accounts for a large proportion of diagnoses. IPF occurs in roughly 3 to 9 people per 100,000 each year in North America and Europe. It’s more common in men, in people over 60, and in those with a family history of the disease. Smoking is a significant risk factor even when no other cause is found.
Symptoms and How They Progress
The earliest and most common symptom is shortness of breath, particularly during physical activity. At first it may feel like being slightly more winded than usual on a walk or climbing stairs. Many people attribute it to aging or being out of shape, which is one reason diagnosis is often delayed. A persistent dry cough that doesn’t produce mucus is the other hallmark symptom.
As the disease progresses, breathlessness worsens and begins to interfere with everyday tasks like getting dressed, cooking, or talking. Fatigue becomes significant because your body is working harder to get the oxygen it needs. Unexplained weight loss can occur. Some people develop a condition called clubbing, where the fingertips widen and the nails curve downward. Clubbing appears in roughly 7% to 52% of people with IPF, depending on how it’s measured, and when present, it can be an early visible clue.
When a doctor listens to the lungs with a stethoscope, they often hear a distinctive sound described as “Velcro crackles,” a fine crackling that sounds like slowly pulling apart a strip of Velcro. This sound comes from the stiff, scarred air sacs popping open during inhalation.
How Pulmonary Fibrosis Is Diagnosed
Diagnosis typically starts with breathing tests called pulmonary function tests. In pulmonary fibrosis, these show a “restrictive” pattern: your lungs can’t hold as much air as they should. Specifically, the total volume of air you can force out in one breath (forced vital capacity, or FVC) drops below 80% of what’s predicted for your age and size, while the ratio of how quickly you can push air out stays normal or even increases. This distinguishes it from conditions like asthma or COPD, where the airways are narrowed rather than the lung tissue itself being stiff.
Another key test measures how well oxygen passes from your air sacs into your blood, called diffusion capacity. In early pulmonary fibrosis, this value can drop below normal (under 75% of predicted) even before other breathing tests show obvious problems.
The most important imaging tool is a high-resolution CT scan of the chest. Doctors look for specific patterns in the scarring. The hallmark of IPF is a pattern called “usual interstitial pneumonia,” which appears as honeycombing, clusters of small, thick-walled air spaces that look like a honeycomb on the scan. This honeycombing typically concentrates in the lower and outer portions of the lungs. When honeycombing isn’t clearly present but there’s a network of fine lines (reticular abnormalities) with distorted airways, it’s classified as “probable” rather than definitive. Sometimes patients are scanned lying face down to improve accuracy and reduce false readings caused by gravity compressing the lower lungs.
If imaging and breathing tests aren’t conclusive, a lung biopsy may be needed. The diagnosis of IPF specifically requires ruling out all other known causes of pulmonary fibrosis, including autoimmune disease, drug reactions, radiation exposure, and occupational dust inhalation.
Treatment Options
There is no cure for pulmonary fibrosis, and existing scar tissue cannot be reversed. Treatment focuses on slowing the rate of decline and managing symptoms.
Two antifibrotic medications are approved for IPF. Both work by interfering with the signaling pathways that drive scar tissue production. In clinical trials, patients taking either drug preserved more lung function than those on placebo. A large meta-analysis found that treated patients retained an average of about 87 milliliters more lung capacity and roughly 3 percentage points more of their predicted forced vital capacity compared to untreated patients. They also walked about 25 meters farther on a six-minute walk test, a standard measure of functional exercise capacity. These differences may sound modest, but in a disease where lung function steadily erodes, slowing that decline meaningfully extends the period of functional independence.
These medications don’t stop the disease entirely, and they come with side effects. Nausea, diarrhea, and liver enzyme changes are common. Your doctor will monitor bloodwork regularly while you’re on treatment.
Supplemental Oxygen
As the disease progresses and blood oxygen levels drop, supplemental oxygen becomes necessary. Oxygen is typically prescribed to keep blood oxygen saturation at or above 96% during activity and rest. Initially you may only need it during exercise, but over time many people require it around the clock. Portable oxygen concentrators make it possible to stay mobile, though managing equipment adds a layer of daily challenge.
Pulmonary Rehabilitation
Pulmonary rehabilitation programs combine supervised exercise, breathing techniques, and education. They don’t change the underlying disease but can improve how efficiently your body uses the oxygen it has, reduce breathlessness during daily activities, and build stamina. For many people, rehab is one of the most tangible improvements in quality of life.
Lung Transplantation
For people with advanced pulmonary fibrosis who are otherwise healthy enough, lung transplantation remains the only option that can significantly extend life. It’s a major surgery with its own risks and lifelong requirements for immune-suppressing medication, but for eligible candidates it can restore years of functional breathing.
Living With Pulmonary Fibrosis
The day-to-day experience of pulmonary fibrosis changes as the disease progresses. Early on, you may notice only mild limitations. Over months to years, activities that once felt routine require more planning: pacing yourself, timing medications, coordinating oxygen equipment, and adjusting expectations for energy levels. Many people find that cold air, humidity, and air pollution noticeably worsen their breathing.
Staying physically active within your limits is one of the most effective things you can do. Even light walking helps maintain muscle conditioning, which reduces how hard your body has to work to perform basic tasks. Vaccinations against respiratory infections like flu, pneumonia, and COVID-19 are important because any lung infection can cause a rapid, sometimes irreversible worsening. Avoiding smoke, dust, and chemical fumes protects the remaining healthy lung tissue.
The psychological toll is significant. Chronic breathlessness is closely linked to anxiety, and the progressive nature of the disease can lead to depression. Support groups, whether in person or online, connect you with others navigating the same challenges and can be a genuine source of practical advice and emotional resilience.